{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:49:25Z","timestamp":1790045365717,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00259-022-06094-z","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T10:12:08Z","timestamp":1672827128000},"page":"1434-1441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE"],"prefix":"10.1007","volume":"50","author":[{"given":"Chayenne H. A. M.","family":"Veerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7767-0393","authenticated-orcid":false,"given":"Hinke","family":"Siebinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-8148","authenticated-orcid":false,"given":"Daphne M. V.","family":"de Vries-Huizing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot E. T.","family":"Tesselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. M. A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8131-5690","authenticated-orcid":false,"given":"Marcel P. M.","family":"Stokkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-3794","authenticated-orcid":false,"given":"Else A.","family":"Aalbersberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"issue":"10","key":"6094_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"issue":"8","key":"6094_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4251\/wjgo.v6.i8.301","volume":"6","author":"WJ Salyers","year":"2014","unstructured":"Salyers WJ, Vega KJ, Munoz JC, Trotman BW, Tanev SS. Neuroendocrine tumors of the gastrointestinal tract: case reports and literature review. World J Gastrointest Oncol. 2014;6(8):301\u201310.","journal-title":"World J Gastrointest Oncol"},{"key":"6094_CR3","doi-asserted-by":"crossref","unstructured":"Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future.\u00a0Int J Mol Sci. 2019;20(12):3049.","DOI":"10.3390\/ijms20123049"},{"issue":"2","key":"6094_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"6094_CR5","first-page":"502","volume":"47","author":"R Cescato","year":"2006","unstructured":"Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47(3):502\u201311.","journal-title":"J Nucl Med"},{"issue":"5","key":"6094_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, H\u00f6rsch D, O\u2019Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6094_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00259-018-4117-x","volume":"46","author":"EA Aalbersberg","year":"2019","unstructured":"Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, Saveur LJ, Valk GD, Tesselaar MET, et al. Influence of lanreotide on uptake of (68)Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging. 2019;46(3):696\u2013703.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"6094_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40644-018-0136-x","volume":"18","author":"MH Cherk","year":"2018","unstructured":"Cherk MH, Kong G, Hicks RJ, Hofman MS. Changes in biodistribution on 68Ga-DOTA-Octreotate PET\/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cancer Imaging. 2018;18(1):3.","journal-title":"Cancer Imaging"},{"issue":"5","key":"6094_CR9","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s11307-021-01600-5","volume":"23","author":"MA Lodge","year":"2021","unstructured":"Lodge MA, Solnes LB, Chaudhry MA, Wahl RL. Prospective within-patient assessment of the impact of an unlabeled octreotide pre-dose on the biodistribution and tumor uptake of (68)Ga DOTATOC as assessed by dynamic whole-body PET in patients with neuroendocrine tumors: implications for diagnosis and therapy. Mol Imaging Biol. 2021;23(5):766\u201374.","journal-title":"Mol Imaging Biol"},{"issue":"12","key":"6094_CR10","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.2967\/jnumed.119.226332","volume":"60","author":"A G\u00e5lne","year":"2019","unstructured":"G\u00e5lne A, Almquist H, Almquist M, Hindorf C, Ohlsson T, Nordenstr\u00f6m E, et al. A prospective observational study to evaluate the effects of long-acting somatostatin analogs on (68)Ga-DOTATATE uptake in patients with neuroendocrine tumors. J Nucl Med. 2019;60(12):1717\u201323.","journal-title":"J Nucl Med"},{"issue":"11","key":"6094_CR11","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2967\/jnumed.111.089276","volume":"52","author":"AR Haug","year":"2011","unstructured":"Haug AR, Rominger A, Mustafa M, Auernhammer C, G\u00f6ke B, Schmidt GP, et al. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET\/CT in patients with neuroendocrine tumors. J Nucl Med. 2011;52(11):1679\u201383.","journal-title":"J Nucl Med"},{"issue":"1","key":"6094_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13550-021-00860-0","volume":"11","author":"U Jahn","year":"2021","unstructured":"Jahn U, Ilan E, Velikyan I, Fr\u00f6ss-Baron K, Lubberink M, Sundin A. Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by (68)Ga-DOTATOC PET\/CT. EJNMMI Res. 2021;11(1):118.","journal-title":"EJNMMI Res"},{"issue":"2","key":"6094_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2967\/jnumed.117.192203","volume":"59","author":"N Ayati","year":"2018","unstructured":"Ayati N, Lee ST, Zakavi R, Pathmaraj K, Al-Qatawna L, Poon A, et al. Long-acting somatostatin analog therapy differentially alters (68)Ga-DOTATATE uptake in normal tissues compared with primary tumors and metastatic lesions. J Nucl Med. 2018;59(2):223\u20137.","journal-title":"J Nucl Med"},{"issue":"9","key":"6094_CR14","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4158\/EP151172.OR","volume":"22","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (Elect): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068\u201380.","journal-title":"Endocr Pract"},{"issue":"11","key":"6094_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260073","volume":"16","author":"DMV de Vries-Huizing","year":"2021","unstructured":"de Vries-Huizing DMV, Versleijen MWJ, Sinaasappel M, Walraven I, Geluk-Jonker MM, Tesselaar MET, et al. Haematotoxicity during peptide receptor radionuclide therapy: baseline parameters differences and effect on patient\u2019s therapy course. PLoS ONE. 2021;16(11): e0260073.","journal-title":"PLoS ONE"},{"key":"6094_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2021.122605","volume":"1171","author":"L van Andel","year":"2021","unstructured":"van Andel L, Aalbersberg EA, Geluk-Jonker MM, Stokkel MPM, Beijnen JH, Hendrikx JJMA. The development and validation of a high performance liquid chromatography method to determine the radiochemical purity of [177Lu]Lu-HA-DOTA-TATE in pharmaceutical preparations. J Chromatogr B. 2021;1171: 122605.","journal-title":"J Chromatogr B"},{"issue":"1","key":"6094_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40658-015-0127-y","volume":"2","author":"M Sandstr\u00f6m","year":"2015","unstructured":"Sandstr\u00f6m M, Ilan E, Karlberg A, Johansson S, Freedman N, Garske-Rom\u00e1n U. Method dependence, observer variability and kidney volumes in radiation dosimetry of 177Lu-DOTATATE therapy in patients with neuroendocrine tumours. EJNMMI Physics. 2015;2(1):24.","journal-title":"EJNMMI Physics"},{"issue":"2","key":"6094_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00259-009-1216-8","volume":"37","author":"M Sandstr\u00f6m","year":"2010","unstructured":"Sandstr\u00f6m M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging. 2010;37(2):212\u201325.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"6094_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/acm2.12991","volume":"21","author":"DMV Huizing","year":"2020","unstructured":"Huizing DMV, Sinaasappel M, Dekker MC, Stokkel MPM, de Wit-van der Veen BJ. (177) Lutetium SPECT\/CT: evaluation of collimator, photopeak and scatter correction. J Appl Clin Med Phys. 2020;21(9):272\u20137.","journal-title":"J Appl Clin Med Phys."},{"issue":"1","key":"6094_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40658-020-0278-3","volume":"7","author":"SMB Peters","year":"2020","unstructured":"Peters SMB, Meyer Viol SL, van der Werf NR, de Jong N, van Velden FHP, Meeuwis A, et al. Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT\/CT systems. EJNMMI Phys. 2020;7(1):9.","journal-title":"EJNMMI Phys"},{"issue":"5","key":"6094_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3413\/Nukmed-0581-13-05","volume":"52","author":"S Ezziddin","year":"2013","unstructured":"Ezziddin S, Reichmann K, Yong-Hing C, Damm M, Risse J, Ahmadzadehfar H, et al. Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate. Nuklearmedizin. 2013;52(5):170\u20137.","journal-title":"Nuklearmedizin."},{"issue":"S4","key":"6094_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/cncr.24796","volume":"116","author":"M Garkavij","year":"2010","unstructured":"Garkavij M, Nickel M, Sj\u00f6green-Gleisner K, Ljungberg M, Ohlsson T, Wing\u00e5rdh K, et al. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(S4):1084\u201392.","journal-title":"Cancer"},{"key":"6094_CR23","unstructured":"Common Terminology Criteria for Adverse Events v5.0. [Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm.] Accessed on Nov 2, 2022."},{"issue":"5","key":"6094_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1507\/endocrj.52.605","volume":"52","author":"Y Taniyama","year":"2005","unstructured":"Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J. 2005;52(5):605\u201311.","journal-title":"Endocr J"},{"issue":"7","key":"6094_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s002590100541","volume":"28","author":"JC Reubi","year":"2001","unstructured":"Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28(7):836\u201346.","journal-title":"Eur J Nucl Med"},{"issue":"3","key":"6094_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, Konijnenberg MW, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2016;43(3):453\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6094_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"6094_CR28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"6094_CR29","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Lind\u00e9n O, Flux G. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"6094_CR30","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","volume":"45","author":"U Garske-Rom\u00e1n","year":"2018","unstructured":"Garske-Rom\u00e1n U, Sandstr\u00f6m M, Fr\u00f6ss Baron K, Lundin L, Hellman P, Welin S, et al. Prospective observational study of (177)Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6094_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40658-016-0157-0","volume":"3","author":"J Svensson","year":"2016","unstructured":"Svensson J, Ryd\u00e9n T, Hagmarker L, Hemmingsson J, W\u00e4ngberg B, Bernhardt P. A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Phys. 2016;3(1):21.","journal-title":"EJNMMI Phys"},{"key":"6094_CR32","unstructured":"Samenvatting van de productkenmerken Somatuline Autogel [Available from: https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h26301_smpc.pdf]. Accessed 1 Aug\u00a02022."},{"key":"6094_CR33","unstructured":"Summary of product characteristics, labelling and package leaflet Sandostatin LAR [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/sandostatin-lar-article-30-referral-annex-iii_en.pdf]. Acessed 1 Aug 2022."},{"issue":"1","key":"6094_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40658-020-0273-8","volume":"7","author":"A Chicheportiche","year":"2020","unstructured":"Chicheportiche A, Ben-Haim S, Grozinsky-Glasberg S, Oleinikov K, Meirovitz A, Gross DJ, et al. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. EJNMMI Phys. 2020;7(1):5.","journal-title":"EJNMMI Phys"},{"issue":"1","key":"6094_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40658-018-0232-9","volume":"5","author":"KP Willowson","year":"2018","unstructured":"Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following (177)Lu-DOTATATE (\u2018Lutate\u2019) therapy. EJNMMI Phys. 2018;5(1):33.","journal-title":"EJNMMI Phys"},{"issue":"7","key":"6094_CR36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.120.254656","volume":"62","author":"X Hou","year":"2021","unstructured":"Hou X, Brosch J, Uribe C, Desy A, B\u00f6ning G, Beauregard J-M, et al. Feasibility of single-time-point dosimetry for radiopharmaceutical therapies. J Nucl Med. 2021;62(7):1006\u201311.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06094-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-06094-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06094-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T04:44:38Z","timestamp":1679373878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-06094-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["6094"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-06094-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Research Board (IRBd21-187, approved July 26, 2021].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients signed a general consent for the use of their data in retrospective studies.Consent for publication.Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}